DCDS 0780A

Drug Profile

DCDS 0780A

Alternative Names: DCDS0780A

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Apr 2015 Roche plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) is USA (NCT02453087)
  • 15 Apr 2015 Preclinical trials in Non-Hodgkin's lymphoma in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top